The impact of SARS-CoV-2 infection on the survival in NSCLC patients undergoing immunotherapy

Melek Özdemir; Gamze Gokoz Dogu; Burcu Yapar Taşköylü; Arzu Yaren; Serkan Değirmencioğlu; Atike Gökçen Demiray; Anıl Erdemir; Burçin Çakan Demirel; Tolga Doğan; Taliha Güçlü Kantar; Semra Taş; Bedriye Açıkgöz Yıldız; Gamze Serin Özel; Ceren Mordağ Çiçek

Makale detayları

The impact of SARS-CoV-2 infection on the survival in NSCLC patients undergoing immunotherapy

Yazarlar:

Melek Özdemir | Gamze Gokoz Dogu | Burcu Yapar Taşköylü | Arzu Yaren | Serkan Değirmencioğlu | Atike Gökçen Demiray | Anıl Erdemir | Burçin Çakan Demirel | Tolga Doğan | Taliha Güçlü Kantar | Semra Taş | Bedriye Açıkgöz Yıldız | Gamze Serin Özel | Ceren Mordağ Çiçek

Yayıncı:

Pamukkale University

Ana Başlıklar:

İmmünoloji (Diğer) | İç Hastalıkları | Klinik Tıp Bilimleri (Diğer)

Dergi:

Pamukkale Tıp Dergisi Vol.18 Issue 4, pp.733-747

Belge Tipi:

Makale

Yayın Tarihi:

1/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001340995

pISSN:

1308-0865

Anahtar kelimeler:

Özet:

 Purpose: The impact of immune checkpoint inhibitor ICI utilisation on prognosis and the prognostic value of inflammatory markers neutrophil-lymphocyte ratio NLR, platelet-lymphocyte ratio PLR, systemic immune inflammation score SII, prognostic nutrition index PNI in patients with advanced non-small cell lung cancer NSCLC were evaluated in the context of the ongoing pandemic. The cut-off values of the prognostic markers were obtained from clinical studies in the literature. Materials and methods: A non-probability sequential sampling technique ensured the study included 104 patients who had received ICI at any stage. Laboratory tests taken at the outset of ICI treatment were recorded, and NLR, PLR, PNI and SII were calculated and 2-year median overall survival mOS was then evaluated. Results: The median age of the cohort was 63.99 years, with 98 of patients being male. Infection with SARS-CoV-2 virus was documented in 29 patients 27.9. The survival results were similar in both groups when the cut-off values were applied for inflamatuar markers. The two-year mOS was 22 months 44.1. The two-year survival rate of patients who developed a SARS-CoV-2 infection following the administration of an ICI at any stage of treatment was inferior to that of ICI recipients who did not develop the infection 14.3 months vs. 53.6 months; p0.001. In contrast with previous studies, 57.1 of patients with a PD-L1 level of 0 survived for two years, while only 10 with levels of 1-49 did so p0.010. Conclusion: This study revealed a significantly lower two-year survival rate in patients with a positive diagnosis for SARS-CoV-2 during ICI use compared to those without a positive diagnosis 14.3 months; 53.6 months; p0.001. In the course of our research, we were unsuccessful in identifying a prognostic marker that could be useful in predicting survival in NSCLC patients using ICI in the context of the pandemic. This investigation yielded findings that differed from the conclusions of previous studies. It demonstrated that, contrary to the prevailing view, the two-year survival rate was higher in patients exhibiting PD-L1 0 than in those with PD-L1:1-49 57.1; 10, p0.010.

 Purpose: The impact of immune checkpoint inhibitor ICI utilisation on prognosis and the prognostic value of inflammatory markers neutrophil-lymphocyte ratio NLR, platelet-lymphocyte ratio PLR, systemic immune inflammation score SII, prognostic nutrition index PNI in patients with advanced non-small cell lung cancer NSCLC were evaluated in the context of the ongoing pandemic. The cut-off values of the prognostic markers were obtained from clinical studies in the literature. Materials and methods: A non-probability sequential sampling technique ensured the study included 104 patients who had received ICI at any stage. Laboratory tests taken at the outset of ICI treatment were recorded, and NLR, PLR, PNI and SII were calculated and 2-year median overall survival mOS was then evaluated. Results: The median age of the cohort was 63.99 years, with 98 of patients being male. Infection with SARS-CoV-2 virus was documented in 29 patients 27.9. The survival results were similar in both groups when the cut-off values were applied for inflamatuar markers. The two-year mOS was 22 months 44.1. The two-year survival rate of patients who developed a SARS-CoV-2 infection following the administration of an ICI at any stage of treatment was inferior to that of ICI recipients who did not develop the infection 14.3 months vs. 53.6 months; p0.001. In contrast with previous studies, 57.1 of patients with a PD-L1 level of 0 survived for two years, while only 10 with levels of 1-49 did so p0.010. Conclusion: This study revealed a significantly lower two-year survival rate in patients with a positive diagnosis for SARS-CoV-2 during ICI use compared to those without a positive diagnosis 14.3 months; 53.6 months; p0.001. In the course of our research, we were unsuccessful in identifying a prognostic marker that could be useful in predicting survival in NSCLC patients using ICI in the context of the pandemic. This investigation yielded findings that differed from the conclusions of previous studies. It demonstrated that, contrary to the prevailing view, the two-year survival rate was higher in patients exhibiting PD-L1 0 than in those with PD-L1:1-49 57.1; 10, p0.010.

 Purpose: The impact of immune checkpoint inhibitor ICI utilisation on prognosis and the prognostic value of inflammatory markers neutrophil-lymphocyte ratio NLR, platelet-lymphocyte ratio PLR, systemic immune inflammation score SII, prognostic nutrition index PNI in patients with advanced non-small cell lung cancer NSCLC were evaluated in the context of the ongoing pandemic. The cut-off values of the prognostic markers were obtained from clinical studies in the literature. Materials and methods: A non-probability sequential sampling technique ensured the study included 104 patients who had received ICI at any stage. Laboratory tests taken at the outset of ICI treatment were recorded, and NLR, PLR, PNI and SII were calculated and 2-year median overall survival mOS was then evaluated. Results: The median age of the cohort was 63.99 years, with 98 of patients being male. Infection with SARS-CoV-2 virus was documented in 29 patients 27.9. The survival results were similar in both groups when the cut-off values were applied for inflamatuar markers. The two-year mOS was 22 months 44.1. The two-year survival rate of patients who developed a SARS-CoV-2 infection following the administration of an ICI at any stage of treatment was inferior to that of ICI recipients who did not develop the infection 14.3 months vs. 53.6 months; p0.001. In contrast with previous studies, 57.1 of patients with a PD-L1 level of 0 survived for two years, while only 10 with levels of 1-49 did so p0.010. Conclusion: This study revealed a significantly lower two-year survival rate in patients with a positive diagnosis for SARS-CoV-2 during ICI use compared to those without a positive diagnosis 14.3 months; 53.6 months; p0.001. In the course of our research, we were unsuccessful in identifying a prognostic marker that could be useful in predicting survival in NSCLC patients using ICI in the context of the pandemic. This investigation yielded findings that differed from the conclusions of previous studies. It demonstrated that, contrary to the prevailing view, the two-year survival rate was higher in patients exhibiting PD-L1 0 than in those with PD-L1:1-49 57.1; 10, p0.010.

 Amaç: İleri evre küçük hücreli dışı akciğer kanserli NSCLC hastalarda immün kontrol noktası inhibitörü ICI kullanımının prognoz üzerindeki etkisi ve inflamatuar belirteçlerin nötrofil-lenfosit oranı NLR, trombosit-lenfosit oranı PLR, sistemik immün inflamasyon skoru SII, prognostik beslenme indeksi PNI prognostik değeri devam eden pandemi bağlamında değerlendirildi. Gereç ve yöntem: Olasılıksız sıralı örnekleme tekniği ile belirlenen tedavinin herhangi bir basamağında ICI almış 104 hastanın çalışmaya dahil edildi. ICI tedavisinin başlangıcında alınan laboratuvar testleri kaydedilerek; NLR, PLR, PNI ve SII hesaplandı. Ardından 2 yıllık medyan genel sağkalım mOS değerlendirildi. Prognostik belirteçlerin cut-off değerleri literatürde yer alan klinik çalışmalardan elde edildi. Bulgular: Ortalama tanı yaşı 63,99 yıl olup hastaların 98i erkekti. SARS-CoV-2 virüsü ile enfekte olan 29 hasta 27,9 vardı. Enflamatuar belirteçler için kesme değerler uygulandığında sağkalım sonuçları her iki grupta da benzerdi. İki yıllık mOS 22 aydı 44,1. Tedavinin herhangi bir aşamasında ICI uygulanmasını takiben SARS-CoV-2 enfeksiyonu gelişen hastaların iki yıllık sağkalım oranı, enfeksiyon gelişmeyen ICI alıcılarınınkinden daha düşüktü 14,3 ay; 53,6 ay; p0,001. Önceki çalışmaların aksine, PD-L1 düzeyi 0 olan hastaların 57,1i iki yıl boyunca hayatta kalırken, 1-49 düzeyine sahip hastaların yalnızca 10u hayatta kalmıştır p0,010. Sonuç: Bu çalışma, ICI kullanımı sırasında SARS-CoV-2 için pozitif tanı alan hastalarda, pozitif tanı almayanlara kıyasla iki yıllık sağkalım oranının anlamlı derecede düşük olduğunu ortaya koymuştur 14,3 ay; 53,6 ay; p0,001. Araştırmamızda, pandemi döneminde ICI kullanan NSCLC hastalarında sağkalımı tahmin etmede yararlı olabilecek bir prognostik belirteç tanımlayamadık. Bu araştırma, önceki çalışmaların sonuçlarından farklı olarak, iki yıllık sağkalım oranının PD-L1:0 olan hastalarda PD-L1:1-49 gösterenlere göre daha yüksek olduğunu göstermiştir 57,1; 10, p0,010.

Makale detayları

The impact of SARS-CoV-2 infection on the survival in NSCLC patients undergoing immunotherapy

Yayıncı:

Pamukkale University

Ana Başlıklar:

İmmünoloji (Diğer) | İç Hastalıkları | Klinik Tıp Bilimleri (Diğer)

Dergi:

Pamukkale Tıp Dergisi Vol.18 Issue 4, pp.733-747

Belge Tipi:

Makale

Yayın Tarihi:

1/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001340995

pISSN:

1308-0865

NSCLC

COVID-19

immunotherapyNSCLC

COVID-19

immünoterapi

Sayı

Makale detayları

The impact of SARS-CoV-2 infection on the survival in NSCLC patients undergoing immunotherapy

Yayıncı: Pamukkale University

Ana Başlıklar: İmmünoloji (Diğer) | İç Hastalıkları | Klinik Tıp Bilimleri (Diğer)

Dergi: Pamukkale Tıp Dergisi Vol.18 Issue 4, pp.733-747

Belge Tipi: Makale

Yayın Tarihi: 1/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001340995

pISSN: 1308-0865

NSCLC

COVID-19

immunotherapyNSCLC

COVID-19

immünoterapi

Sayı

Yayıncı:

Pamukkale University

Ana Başlıklar:

İmmünoloji (Diğer) | İç Hastalıkları | Klinik Tıp Bilimleri (Diğer)

Dergi:

Pamukkale Tıp Dergisi Vol.18 Issue 4, pp.733-747

Belge Tipi:

Makale

Yayın Tarihi:

1/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001340995

pISSN:

1308-0865